Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
D. Lansing Taylor
University of Pittsburgh at Pittsburgh, Department: Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
SpIntellx
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Taylor's conflict arises due to his interest as an inventor of the intellectual property being evaluated/developed in this bench research, which the University of Pittsburgh licensed to SpIntellx. Dr. Taylor also holds an ownership interest in SpIntellx and serves as the company's Chairman and Treasurer.
Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images
This proposal will build and develop interactive software for use by cancer biologists and clinicians to quantitate, interpret and visualize spatial intra-tumor heterogeneity (ITH) in tumor tissue samples imaged as multiplexed (< 7 biomarkers) and hyperplexed (> 7 biomarkers) immunofluorescence data. Our studies will inform associations between heterogeneity and clinical information (e.g., drug response, metastasis risk, and outcome). Our algorithms will identify clinically relevant biomarkers in the context of any particular cancer application and as a first step toward constructing diagnostics based on both cancer biomarker expression levels and spatial relationships between cancer and stromal cells. Our software will also help reduce intra- and inter-observer variability in quantifying heterogeneity at diagnostic laboratories and will support the development of an ITH index that, combined with genetic rating scales (e.g., OncotypeDx), will better predict tumor progression and patient outcome.
Filed on August 13, 2018.
Tell us what you know about D. Lansing Taylor's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
D. Lansing Taylor filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| D. Lansing Taylor | University of Pittsburgh at Pittsburgh | Conflict of Interest | SpIntellx | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.